Correction to: EJNMMI Research (2018) 8:10. https://doi.org/10.1186/s13550-017-0356-2
Following publication of the original article [1], the authors identified several calculation errors in the second and seventh paragraphs of the discussion section.
Please find the corrected second paragraph (with the corrected values denoted in italics) below:
“Based on information from the US National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) of the American Cancer Society (database: 2010 to 2012), the risk for developing cancer is 42% in the males and 38% in females [2]. The lifetime overall risk in male population is 2864 times higher than the mean excess lifetime risk of our patients. Compared to the female population, the mean excess lifetime risk of our patients is approximately 1817 times lower for all cancer types [2]. Similar results are shown for a comparison with the risk database (2012) from the Robert Koch Institute’s (RKI) German Centre for Cancer Registry Data [3]. In Germany, the male population showed a lifetime overall risk of 50% for developing cancer [3], which is about 3440 times higher than the mean excess risk for our male patients. The female population has a lifetime overall risk of 43% for developing cancer, which is approximately 2084 times higher than the excess risk for our female patients [3]. According to these comparisons, the overall additional risk for our patient group can be considered as very low.”
And please find here the corrected seventh paragraph (with the corrected values denoted in italics):
“Compared to our patient risk data, the lifetime overall risk for both genders of the general population for developing bladder cancer is above the mean excess lifetime risk, with values of approximately 329 (SEER) and 214 (RKI) times higher for males and 73 (SEER) and 51 (RKI) times higher for females [2, 3]. Bladder voiding influenced the risk, in comparison to the patient group without bladder voiding during the examination, the mean excess lifetime risk values of the patient group with voiding was 58% lower.”
The authors apologize for any inconvenience caused.
References
Soares Machado J, Tran-Gia J, Schlögl S, et al. Biokinetics, dosimetry, and radiation risk in infants after 99mTc-MAG3 scans. EJNMMI Res. 2018;8:10. https://doi.org/10.1186/s13550-017-0356-2.
American Cancer Society. Lifetime Risk of Developing or Dying from Cancer 2016. https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html#written_by.
Cancer in Germany 2011/2012. [Internet]. 2016 [cited 28/05/2017]. http://www.rki.de/EN/Content/Health_Monitoring/Cancer_Registry/cancer_registry_node.html.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Soares Machado, J., Tran-Gia, J., Schlögl, S. et al. Correction to: Biokinetics, dosimetry and radiation risk in infants after 99mTc-MAG3 scans. EJNMMI Res 11, 101 (2021). https://doi.org/10.1186/s13550-021-00836-0
Published:
DOI: https://doi.org/10.1186/s13550-021-00836-0